Skip to main content
Clinical Trials/NCT04457544
NCT04457544
Recruiting
N/A

Spontaneous Coronary Artery Dissection (SCAD) National Swiss Registry (SwissSCAD)

Dr. Sophie Degrauwe1 site in 1 country1,000 target enrollmentAugust 12, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Spontaneous Coronary Artery Dissection
Sponsor
Dr. Sophie Degrauwe
Enrollment
1000
Locations
1
Primary Endpoint
Incidence of safety events at 30 days
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Spontaneous coronary artery dissection (SCAD), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death.

Timely diagnosis of SCAD as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood.

In this context, we designed the SwissSCAD registry, a large, observational, prospective, cohort study, to describe the natural history of SCAD, its outcomes and its treatments.

Registry
clinicaltrials.gov
Start Date
August 12, 2020
End Date
June 30, 2030
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Dr. Sophie Degrauwe
Responsible Party
Sponsor Investigator
Principal Investigator

Dr. Sophie Degrauwe

Doctor

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • Subject is ≥18 years of age.
  • Patient presenting newly diagnosed SCAD or diagnosed with SCAD within the last 5 years.
  • Subject must be willing to sign a Patient Informed Consent (PIC).

Exclusion Criteria

  • Patient unwilling or unable to provide informed consent.
  • Patients with atherosclerotic or iatrogenic coronary dissection.

Outcomes

Primary Outcomes

Incidence of safety events at 30 days

Time Frame: 30 days

Incidence of Major cardiovascular outcomes (MACE) at 30 days

Secondary Outcomes

  • Incidence of safety events at 1 year(1 year)
  • Incidence of safety events at 5 years(5 years)

Study Sites (1)

Loading locations...

Similar Trials